According to the World Health Organization, cardiovascular diseases are the leading cause of death globally. The American Heart Association estimates current direct costs for treatment of cardiovascular disease in the U.S. to be $277 billion annually and expects costs to grow to $655 billion by 2035. Venture capital investment for cardiovascular-focused therapeutic companies remains low relative to other therapeutic areas. Recently reported data from a few small biotechs suggest there is still activity in clinical development despite recent exits out of cardiovascular disease by larger pharmaceutical companies. Attend to learn more about companies in this space particularly in hypertension and heart failure, investor perspectives, and the latest data from BIO’s report on cardiovascular therapeutics, the 5th volume in the series on highly prevalent chronic diseases.